VivoSeq
Other

Rifaximin

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Rifaximin is an early-stage landscape with 0 programs across 1 company. The most active players are Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed7 · 70%
Terminated1 · 10%
Unknown status1 · 10%
Not yet recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Efficacy of Rifaximin With NAC in IBS-D
Not yet recruiting·MMark Pimentel, MD·Phase 2·NCT06727422·225 enrolled
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01466595·73 enrolled
Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers
Completed·BBausch Health Americas, Inc.·Phase 1·NCT04529811·124 enrolled
The Rifaximin Study in CVID
Completed·OOslo University Hospital·Phase 4·NCT01946906·40 enrolled
Blood Lipopolysaccharide (LPS) Rifaximin Study
Completed·—·Phase 2·NCT02124512·12 enrolled
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
Completed·SShanghai Zhongshan Hospital·N/A·NCT02991612·80 enrolled
Efficacy of Rifaximin in Preventing Campylobacteriosis
Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 2/3·NCT02280044·30 enrolled
Rifaximin for Chronic Immune Activation in People With HIV
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT01866826·46 enrolled
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
Terminated·BBausch Health Americas, Inc.·Phase 4·NCT03818672·5 enrolled
Rifaximin Therapy vs Low FODMAP Diet In IBS
Unknown status·UUniversity of Malaya·Phase 4·NCT04841980·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)